Skip to main content

Shendelman Shoshana's Form 4 filing

Applied Therapeutics, Inc. (APLT) · filed Sep 14, 2021

Accession no.
0001209191-21-055932
Filed
Sep 14, 2021
Trade date
Sep 13-14, 2021
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions. Open-market purchases total $145.1K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Shendelman ShoshanaCIK 0001775490Director, Officer (President and CEO), 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 13, 2021Common StockPPurchaseAcquired+701$14.69F2+$10,297.69354,986Direct
Sep 14, 2021Common StockPPurchaseAcquired+9,300$14.49F3+$134,757364,286Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Weighted average price. These shares were purchased by Dr. Shendelman in multiple transactions at prices ranging from $14.6500 to $14.7300 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F3

Weighted average price. These shares were purchased by Dr. Shendelman in multiple transactions at prices ranging from $14.2700 to $14.6000 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)